Early eGFR Dip Likely Doesn’t Hinder SGLT2 Inhibitor’s Kidney Benefits

(MedPage Today) — The SGLT2 inhibitor empagliflozin (Jardiance) reduced the risk of creatinine increases and acute kidney injury (AKI) even in those with an early dip in estimated glomerular filtration rate (eGFR), according to a meta-analysis…